Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spontaneous metastasis xenograft models link CD44 isoform 4 to angiogenesis, hypoxia, EMT and mitochondria-related pathways in colorectal cancer.
Everest-Dass A, Nersisyan S, Maar H, Novosad V, Schröder-Schwarz J, Freytag V, Stuke JL, Beine MC, Schiecke A, Haider MT, Kriegs M, Elakad O, Bohnenberger H, Conradi LC, Raygorodskaya M, Krause L, von Itzstein M, Tonevitsky A, Schumacher U, Maltseva D, Wicklein D, Lange T. Everest-Dass A, et al. Among authors: von itzstein m. Mol Oncol. 2024 Jan;18(1):62-90. doi: 10.1002/1878-0261.13535. Epub 2023 Nov 3. Mol Oncol. 2024. PMID: 37849446 Free PMC article.
Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.
Mu-Mosley H, von Itzstein MS, Fattah F, Liu J, Zhu C, Xie Y, Wakeland EK, Park JY, Kahl BS, Diefenbach CS, Gerber DE. Mu-Mosley H, et al. Among authors: von itzstein ms. Oncoimmunology. 2024 May 9;13(1):2351255. doi: 10.1080/2162402X.2024.2351255. eCollection 2024. Oncoimmunology. 2024. PMID: 38737792 Free PMC article. Clinical Trial.
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
von Itzstein MS, Yang Y, Wang Y, Hsiehchen D, Sheffield TY, Fattah F, Popat V, Ahmed M, Homsi J, Dowell JE, Rashdan S, Lohrey J, Hammers HJ, Hughes RS, Wang T, Xie Y, Gerber DE. von Itzstein MS, et al. Front Immunol. 2024 Apr 16;15:1351739. doi: 10.3389/fimmu.2024.1351739. eCollection 2024. Front Immunol. 2024. PMID: 38690281 Free PMC article.
pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding.
Han Y, Yang Y, Tian Y, Fattah FJ, von Itzstein MS, Hu Y, Zhang M, Kang X, Yang DM, Liu J, Xue Y, Liang C, Raman I, Zhu C, Xiao O, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Pan K, Wu F, Gibbons D, Wang X, Yee C, Huang J, Reuben A, Cheng C, Zhang J, Gerber DE, Wang T. Han Y, et al. Among authors: von itzstein ms. bioRxiv [Preprint]. 2023 Dec 12:2023.12.01.569599. doi: 10.1101/2023.12.01.569599. bioRxiv. 2023. PMID: 38105939 Free PMC article. Preprint.
T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J, Park JY, von Itzstein MS, Hsiehchen D, Fattah F, Gwin M, Catalan R, Khan S, Raj P, Wakeland EK, Xie Y, Gerber DE. Ostmeyer J, et al. Among authors: von itzstein ms. J Immunother Cancer. 2023 Aug;11(8):e006437. doi: 10.1136/jitc-2022-006437. J Immunother Cancer. 2023. PMID: 37580069 Free PMC article.
240 results